Tag Archives: Ram Selvaraju

Analysts’ Top Healthcare Picks: Axsome Therapeutics (AXSM), Akebia Therapeutics (AKBA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Axsome Therapeutics (AXSM – Research Report) and Akebia Therapeutics (AKBA – Research Report) with bullish sentiments. Axsome Therapeutics (AXSM) In a report

What Made H.C. Wainwright Downgrade Inovio Pharmaceuticals’ Stock?

In a report released today, Ram Selvaraju from H.C. Wainwright downgraded Inovio Pharmaceuticals (INO – Research Report) to Hold. The company’s shares closed last Friday at $29.98. According to TipRanks.com, Selvaraju is a top 100 analyst with an average return

Oramed Pharmaceuticals (ORMP) Receives a Rating Update from a Top Analyst

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Oramed Pharmaceuticals (ORMP – Research Report) today and set a price target of $16.00. The company’s shares closed last Friday at $4.05. According to TipRanks.com, Selvaraju is a top 100

Analysts Offer Insights on Healthcare Companies: Evoke Pharma (NASDAQ: EVOK) and Summit Therapeutics (NASDAQ: SMMT)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Evoke Pharma (EVOK – Research Report) and Summit Therapeutics (SMMT – Research Report) with bullish sentiments. Evoke Pharma (EVOK) H.C. Wainwright analyst

Anavex Life Sciences (AVXL) Receives a Rating Update from a Top Analyst

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Anavex Life Sciences (AVXL – Research Report), with a price target of $12.00. The company’s shares closed last Monday at $4.08. According to TipRanks.com, Selvaraju

Immunic (IMUX) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Immunic (IMUX – Research Report) today and set a price target of $45.00. The company’s shares closed last Monday at $11.13. According to TipRanks.com, Selvaraju is a top 100 analyst